Market LIVE
Published markets; coverage varies by country
Product profile · United States

NORTHERA

 ·  Patent Litigation & Settlement History ↓

IngredientDROXIDOPA
Application typeNDA
Application203202
Product002
Dosage formCAPSULE
RouteORAL
Strength200MG
Approval date2014-02-18
Marketing statusPrescription
Status event—
ApplicantLUNDBECK NA LTD
Product source

Current GenericRadar decision

Year2021
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2021-02-18
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2021-02-18
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
211652 / 002FINAL_APPROVAL · FINAL_APPROVED2021-02-18—LUPIN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211741 / 002FINAL_APPROVAL · FINAL_APPROVED2021-02-18—MSN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211818 / 002FINAL_APPROVAL · FINAL_APPROVED2021-02-18—ZYDUS PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212835 / 002FINAL_APPROVAL · FINAL_APPROVED2021-02-18—HIKMA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213162 / 002FINAL_APPROVAL · FINAL_APPROVED2021-02-18—TEVA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213661 / 002FINAL_APPROVAL · FINAL_APPROVED2021-02-18—UPSHER SMITH LABORATORIES LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213911 / 002FINAL_APPROVAL · FINAL_APPROVED2021-02-18—ALKEM LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214017 / 002FINAL_APPROVAL · FINAL_APPROVED2021-02-18—SCIEGEN PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214384 / 002FINAL_APPROVAL · FINAL_APPROVED2021-02-18—SUN PHARMACEUTICAL INDUSTRIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214387 / 002FINAL_APPROVAL · FINAL_APPROVED2021-02-18—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214391 / 002FINAL_APPROVAL · FINAL_APPROVED2021-02-18—JUBILANT CADISTA PHARMACEUTICALS INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213033 / 002FINAL_APPROVAL · FINAL_APPROVED2021-04-28—BIONPHARMA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214543 / 002FINAL_APPROVAL · FINAL_APPROVED2021-05-05—SOMERSET THERAPEUTICS LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211726 / 003FINAL_APPROVAL · FINAL_APPROVED2021-08-09—ANNORA PHARMA PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215265 / 002FINAL_APPROVAL · FINAL_APPROVED2021-11-01—ADAPTIS PHARMA PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214217 / 002FINAL_APPROVAL · FINAL_APPROVED2022-05-05—CHARTWELL RX SCIENCES LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 16 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
211652 / 002LUPIN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2021-02-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211741 / 002MSN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2021-02-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211818 / 002ZYDUS PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2021-02-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212835 / 002HIKMA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2021-02-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213162 / 002TEVA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2021-02-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213661 / 002UPSHER SMITH LABORATORIES LLCFINAL_APPROVAL · FINAL_APPROVED2021-02-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213911 / 002ALKEM LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2021-02-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214017 / 002SCIEGEN PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2021-02-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214384 / 002SUN PHARMACEUTICAL INDUSTRIES LTDFINAL_APPROVAL · FINAL_APPROVED2021-02-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214387 / 002AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2021-02-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214391 / 002JUBILANT CADISTA PHARMACEUTICALS INCFINAL_APPROVAL · FINAL_APPROVED2021-02-18 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213033 / 002BIONPHARMA INCFINAL_APPROVAL · FINAL_APPROVED2021-04-28 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214543 / 002SOMERSET THERAPEUTICS LLCFINAL_APPROVAL · FINAL_APPROVED2021-05-05 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211726 / 003ANNORA PHARMA PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2021-08-09 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215265 / 002ADAPTIS PHARMA PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2021-11-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214217 / 002CHARTWELL RX SCIENCES LLCFINAL_APPROVAL · FINAL_APPROVED2022-05-05 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2021-02-18TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.